Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer

Sponsor
Qingdao Municipal Hospital
Study ID
NCT02525237
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
  • S-1 — DRUG
    S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity

Study Details

The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Key Dates

Start date
Aug 31, 2015
Status verified
Aug 2015
Primary completion
Aug 31, 2016
Completion
Aug 31, 2017

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib plus S-1
    Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)

Primary Outcome Measure

Progression Free Survival [ Time Frame: Event driven, an expected average of 8 months ]

Central Contacts

Related Studies